Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2012) 29 P213

ICEECE2012 Poster Presentations Calcium & Vitamin D metabolism (73 abstracts)

Serum levels of soluble secreted α-Klotho are decreased in the early stages of chronic kidney disease, making it a probable novel biomarker for early diagnosis

Y. Terada 1 , Y. Shimamura 1 , K. Hamada 1 , K. Inoue 1 , K. Ogata 1 , M. Ishihara 1 , T. Kagawa 1 , M. Inoue 1 , S. Fujimoto 1 , M. Ikebe 2 , K. Yuasa 2 , S. Yamanaka 1 , T. Sugiura 1 & M. Nishiyama 1


1Kochi Medical School, Nankoku, Japan; 2Kochi-Takasu Hospital, Kochi, Japan.


Background: α-Klotho was first identified as an aging gene and was later shown to be a regulator of phosphate metabolism. Fibroblast growth factor 23 (FGF23) is the key regulator of phosphate metabolism. Serum levels of soluble α-Klotho in chronic kidney disease (CKD) patients have not previously been determined, especially in relation with FGF23 and creatinine levels. This study was designed to investigate whether serum soluble α-Klotho levels are modulated by renal function, age, and FGF23 level in CKD patients. This study is the first report on the utility of measuring soluble α-Klotho levels in human CKD.

Methods: A total of 292 CKD patients were enrolled. Serum samples were collected, and FGF23 and soluble α-Klotho levels were measured using enzyme-linked immunosorbent assay kits. In addition, serum creatinine, hemoglobin, albumin, calcium, and phosphate levels were measured.

Results: Serum soluble α-Klotho levels were associated positively with estimated glomerular filtration rate (eGFR) (P<0.0001) and inversely with serum creatinine level (P<0.01). Interestingly, α-Klotho levels were significantly decreased in stage 2 CKD compared with stage 1 (P=0.0001). Serum FGF23 levels were associated positively with serum creatinine and negatively with eGFR. FGF23 levels were significantly increased in stage 5 compared with stage 1 CKD. Soluble α-Klotho was associated inversely with log-transformed FGF23 level (P<0.01).

Conclusion: Our data indicate that soluble α-Klotho levels are significantly decreased in stage 2 CKD compared to stage 1, and not only in the advanced stages of the disease. Soluble α-Klotho may thus represent a new biomarker for the diagnosis of CKD, especially in the early stage.

Declaration of interest: The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research project.

Funding: This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.

Volume 29

15th International & 14th European Congress of Endocrinology

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.